Category stocks

RBC Downgrades ResMed

ResMed downgraded to Sector Perform RBC Capital Markets downgraded ResMed to Sector Perform from Outperform, citing fiscal 2027 challenges. The price target was lowered to $234 from $276. ResMed faces a slew of challenges in the upcoming fiscal year.